A deadly new variant of the Mpox virus has been making its way through countries in Africa, sparking concerns as cases are now being reported in Europe and Asia. The United Kingdom has seen 186 cases of Mpox over the past two years with no reported fatalities. While the less severe Clade 2 variant has been present in the UK since 2022, a more hazardous strain, known as Clade 1b, has been rapidly spreading in African nations, particularly in the Democratic Republic of Congo.
Reports from the Africa Centres for Disease Control and Prevention Epidemic Intelligence have shown a significant increase in cases in Congo, with 19,667 cases and 575 deaths in 2024 alone. The World Health Organisation has declared a global health emergency and is seeking a $135 million fund to combat the spread of the virus. Mpox, belonging to the same virus family as smallpox, presents with milder symptoms like fever, chills, and body aches, but can lead to severe cases with lesions on various parts of the body.
The UK government lists symptoms of Mpox as skin rash, fever, headaches, muscle aches, and more. The current vaccine in the UK targets the Clade 2 variant and is reported to be 70 to 85 percent effective. While the new strain of Mpox has reached countries in Africa, Europe’s first case of Clade 1b Mpox was reported in Sweden and Asia’s first case in Thailand. Despite these reports, the UK authorities assess the risk to the population as low and are focusing on preparedness and vigilance rather than imposing travel restrictions.
In conclusion, the Mpox outbreak has raised concerns globally as the new variant spreads to different regions, with Africa currently facing the most significant impact. As the UK monitors the situation closely, it is essential for healthcare professionals and authorities to remain vigilant and prepared to handle any potential cases that may arise, ensuring the safety and well-being of the population.